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Summary 
IgE-mediated (Type 1) allergy affects more than 25% of the industrialized 
populations. Atopic individuals usually mount IgE responses against innocuous 
environmental antigens, which when re-exposed to binds to effector cell bound IgE, 
causes crosslinking and consequent release of inflammatory mediators to elicit acute 
symptoms of allergy. Allergen specific immunotherapy, based on the administration of 
allergens as vaccines, is the only treatment that is aimed at long term relief of 
symptoms. Currently, it is carried out using natural extracts of allergen sources. This 
study explores the use of hybrids, comprising several allergens linked together, as 
allergy vaccines.  
 
As recombinants, hybrids can be produced in defined composition.  This 
overcomes problems associated with undefined, non-standardized composition of 
natural extracts, such as under-representation of allergens and acquiring new 
sensitizations. Furthermore, most patients are sensitized to more than one allergen and 
even more than one allergen source. The use of hybrid vaccines allows for 
simultaneous immunotherapy against allergy caused by several allergens with the 
production of a single vaccine molecule.  
 
In this study, two hybrid molecules consisting of four major allergens of house 
dust mite Dermatophagoides pteronyssinus were constructed via genetic engineering. 
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Both hybrids induced IgG antibodies in rabbits that were specific to each of their 
component allergens. The induced IgG antibodies further inhibited the binding of 
human IgE antibodies to the individual allergens. By inhibiting the formation of 
IgE-allergen complexes, the downstream IgE-mediated allergic responses could be 
prevented as well, as observed in immunotherapy.  
 
In particular, Der p 7-5 induced specific IgG responses at comparable levels to 
that induced by Der p 5 or Der p 7 alone; the IgG also inhibited IgE binding by 
comparable extents. Therefore, the hybrid could potentially replace both allergens as 
vaccines. 
 
The hybrids exhibited lower IgE binding ability than the individual allergens 
and could be safer vaccines, owing to their inability to elicit in vivo allergenic side 
effects. Together with the ability to induce blocking IgG, both hybrids were potential 
hypoallergenic vaccines for immunotherapy against their component allergens. 
 
This study also demonstrated that the incorporation of allergen, Der p 1, into a 
hybrid molecule led to an increase in Der p 1-specific IgG responses in rabbits, 
corroborating published findings on hybrids of pollen allergens where the hybrids 
similarly exhibited enhanced immunogenicity. Additionally, this study showed that 
alongside the increased immunogenicity, the repertoire of epitopes recognized by IgG 
antibodies that were induced by the hybrids appear to be wider than that induced by the 
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single allergen. While the underlying explanations for the enhancement of 
immunogenicity and the induction of a slightly different IgG repertoire remain to be 
elucidated, the data clearly supported the use of hybrids over other types of allergy 
vaccines such as natural extracts, purified recombinants or recombinant cocktails, none 
of which could resolve the problem of poor vaccine immunogenicity.  
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1 Introduction  
1.1 Allergy 
Allergy is a type one immediate hypersensitivity reaction, in which an 
immunological response is elicited upon exposure to innocuous environmental antigens 
at doses tolerated by normal subjects, producing clinical reactions. Common allergic 
diseases include allergic rhinitis, asthma, atopic eczema, urticaria and systemic 
anaphylaxis. Phenotypically, it is marked by presence of allergen-specific 
immunoglobulin E (IgE), along with mast cell and eosinophil recruitment and 
activation (Wills-Karp et al., 2001).  
 
1.1.1 Mechanism of Allergy 
Some individuals possess a predisposition to develop allergies. The 
susceptibility, termed atopy, is influenced by both genetic and environmental factors. 
In these individuals, allergy is elicited upon first exposure to the allergens (Figure 1). 
Antigen presenting cells in the peripheral tissues, such as dendritic cells and 
macrophages, phagocytose the antigens and migrate towards the lymph nodes, where 
they present antigenic T cell epitopes to naïve CD4+ T cells via appropriate major 
histocompatability complex (MHC) Class II molecules (Mosmann and Livingstone, 
2004). This activates T cells differentiation into T helper two (Th2) cells which secrete 





Figure 1. Mechanism of Allergy. Allergy is initiated during the first exposure to an 
allergen. (A) Allergen-specific IgE antibodies are produced which bind to mast cells 
via FcέRI receptors. (B) During subsequent exposure, allergen binding to effector 
cell-bound specific IgE leads to the cross-linking of FcέRI receptors and the release of 
inflammatory mediators by means of degranulation, resulting in the immediate 
symptoms of allergy. (C) Late phase reaction sometimes follows hours to days 
following exposure, characterized by T cell proliferation and eosinophil recruitment. 
APC, antigen-presenting cell; DC, dendritic cell; TCR, T-cell receptor.  
 
(Adapted from Valenta, 2002) 
 
 
The antigens also bind bone marrow cells (B cells) via specific B cell epitopes. 
Through T-cell-B-cell interactions, secreted IL-4 stimulates isotype switching in 
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activated B cells which then differentiate into plasma cells, producing IgE antibodies 
(Valenta, 2002). The IgE binds with high affinity to their receptors, FcέRI, located on 
the surface of mast cells in tissues and basophils in the blood (Tanabe, 2007). During 
this phase of sensitization, Th2-polarized memory T cells and IgE memory B cells 
(Valenta, 2002) are established. 
 
During subsequent re-exposure, multivalent binding of allergen to bound IgE 
results in crosslinking of IgE receptors (Figure 1B). Degranulation occurs where 
inflammatory mediators such as histamine and leukotrienes are released from mast 
cells (Kemp and Lockey, 2002), resulting in acute allergic reactions.  
 
Late phase allergic reactions can be provoked by the activation of 
allergen-specific T cells after hours to days and this phase is characterized by T cell 
infiltration and eosinophil recruitment. Bound IgE antibodies have also been implicated 
in antigen-presentation to T cells.  
 
1.2 Allergens 
Allergies are initiated by exposure to allergens. These are immunogenic 
antigens present in the environment, typically proteins or glycoproteins, with molecular 
masses of 5-80 kDa (Valenta, 2002). They are able to induce the production of 
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antibodies of the IgE subtype during sensitization; and elicit clinical response to the 
same or similar protein upon subsequent re-exposures (Akdis, 2006).  
 
To date, more than 500 allergens have been characterized (Tanabe, 2007). In 
accordance to the allergen nomenclature established by the Allergen Nomenclature 
Sub-Committee of the Interional Union of Immunological Societies (IUIS), an allergen 
is designated by the first 3 letters of the genus, the first letter of the species name, and 
then a number specifying the order in which the allergen was identified. Homologous 
allergens of related species are assigned to the same number. (Arlian et al., 2001). 
Based on the prevalence of IgE or skin reactivity in sensitized patients, allergens that 
result in noticeable changes in overall extract reactivity upon removal are termed 
‘major allergens’ (Aalberse, 2000).  
 
Overall, the total annual exposure of an individual to allergens is estimated to be 
in the order of micrograms (Cookson, 1999). These typically involve indoor allergen 
sources such as house dust mites, cockroaches, animal danders and moulds and outdoor 
allergens consisting of inhaled grass pollen and fungal spores.  
 
1.2.1 Mite as an important source of indoor allergens 
Mites are the most important source of allergens in the indoor environment. 
Dust mite allergies constitute a significant health problem both worldwide and locally, 
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with more than 50% of allergic patients being sensitized to them (Chew et al., 1999; 
Angus et al., 2004; Weghofer et al., 2005).  
 
Different species of mites thrive in different parts of the world as a result of 
climatic factors like relative humidity and temperature. Consequently, their importance 
as major allergens varies geographically. Allergies due to mites from the genus 
Dermatophagoides are clinically important, affecting up to 10% of general populations 
(Tanabe, 2007). In particular, D. pteronyssinus is the most prevalent in central Europe 
(Hart et al., 1990). 
 
Mite allergens are mainly derived from their bodies and fecal matter (Arlian et 
al., 1987) and are divided into groups based on their biochemical composition, 
sequence homology, and molecular weight (Arlian et al., 2001). A summary of the 













     
1 Cysteine 
protease 
25 70-90 Chua et al., 1988 
     
2 Unknown 14 60-90 Chua et al., 1990 
     
3 Trypsin 28, 30 51-90 Smith et al., 1994 
     
4 Amylase  57, 60 25-46 Lake et al., 1991;  
Mills et al., 1999 
     
5 Unknown 15 9-70 Tovey et al., 1989 
     
6 Chymotrypsin 25 30-40 Yasueda et al., 1993 
     
7 Unknown 22-31 50-62 Shen et al., 1993 
     
8 Glutathione-S-tr
ansferase 
26 40 O’Neill et al., 1994 
     
9 Collagenolytic 
serine protease 
30 >90 King et al., 1996 
     
10 Tropomyosin  33-37 5-80 Asturias et al., 1998 
     
11 Paramyosin 92, 98, 110 80 Tategaki et al., 2000 
     
12 Unknown 14 50 - 
     
13 Fatty acid 
binding protein 
14, 15 10-23 - 
     
14 Apolipophorin 177 30, 39, 70 Epton et al., 2001 
     
15 98 kDa 
chitinase 
98  O’Neil et al., 2006 
     
     












     
16 Gelsolin-like 
protein/ villin 
53 35 - 




53 35 - 
     
18 60 kDa 
chitinase 
60 54 O’Neil et al., 2006 
     
19 Anti-microbial 
peptide 
7.2  - 
     
20 Arginine kinase 40  # 
     
21 Unknown 14  # 
     
† Only references for allergens of Dermatophagoides pteronyssinus are shown.  
# Identified D. pteronyssinus allergens for which the sequence data is either listed in 
WHO/IUIS or Genbank but as yet unpublished.  
 
Table 1. Mite Allergens and Corresponding Biochemical identities. Table shows 
allergens that have been identified and updated with the WHO/IUIS, as of December 
2007. Mite allergens are divided into specific groups based on their biochemical 





1.3 Incidence of Allergy 
The incidence of allergic diseases has risen dramatically over the last two 
decades in western Europe, the United States and Australasia (Mackay and Rosen, 
2001), affecting up to thirty percent of these populations (Crameri and Rhyner, 2006).  
In particular, the prevalence of allergic asthma in industrialized countries has doubled 




At present, allergy treatment mainly includes allergen avoidance and 
pharmacotherapy where drugs such as anti-histamines and corticosteroids are 
administered to reduce the inflammation. The only treatment that provides long lasting 
relief of symptoms is allergen-specific immunotherapy. 
 
1.4.1 Immunotherapy 
Although the mechanisms underlying allergen specific immunotherapy are still 
being elucidated, considerable evidence suggests that it has the character of vaccination 
(Valenta et al., 2004). The disease-eliciting allergens or the derivatives are 
administered to patients in increasing doses over a period of time.  
 
 22 
1.4.2 Molecular effects of immunotherapy  
Immunological responses to allergen specific immunotherapy appear to be 
effected at a very early stage, thresholds for the activation of mast cells and basophils 
appear to be modulated, leading to the desensitization of these effector cells and 
consequently a reduction in IgE mediated histamine release (Pierkes et al., 1999). The 
mechanism underlying the desensitization effect is not understood as yet.  
 
Other effects frequently observed with immunotherapy include the induction of 
allergen specific Treg cells; suppressed proliferative and cytokine responses (Akdis and 
Akdis, 2007). During the course of therapy, the level of specific IgE in the serum has 
been shown to transiently increase before gradually decreasing over a period of months 
of years with treatment. Immunotherapy therapy also frequently induces allergen 
specific IgG antibodies in the serum. These antibodies, in particular, the IgG4 subclass, 
are believed to compete with human IgE for the allergen thus blocking IgE-dependent 
histamine release and the downstream acute phase responses. Recognizing the same 
epitopes as human IgE, IgG had been shown to suppress allergen-specific T cell 
responses in vitro by inhibiting IgE-mediated allergen-presentation to T cells (van 
Neerven et al., 1999; Wachholz et al., 2003).  
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1.4.3 Allergy Vaccines for Immunotherapy 
Currently, allergen-specific immunotherapy is performed using natural allergen 
extracts from the allergen sources. This approach exposes patients all components of 
the natural extracts –allergic and non-allergic– hence subjecting them to new 
sensitizations and the risks thereof (van Hage-Hamsten and Valenta, 2002).  
 
The allergen contents can also vary from batch to batch, depending on factors 
such as contamination with allergens from other sources, extraction procedures, 
proteolysis and degradation of allergens (Linhart and Valenta, 2004). As such, certain 
allergens could potentially be under-represented, contributing in part to the varying 
efficacies of therapy reported.  
 
A major problem associated with allergen specific immunotherapy pertains to 
the induction of local or even severe, life-threatening systemic anaphylaxis. When B 
cell epitope-containing antigens are administered as vaccines, the IgE antibodies could 
bind to the allergens, thereby eliciting the side effects. 
 
Purified recombinant allergens that resemble their natural counterparts in terms 
of structural and immunological characteristics could address the inadequacies of using 
natural extracts pertaining to undefined allergen composition. Not only can they be 
produced with high batch-to-batch consistency, the use of native-like recombinants 
permits the combination of various allergens into vaccine cocktails tailored according 
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to the sensitization profiles of patients while eliminating the possibility of new 
sensitizations at the same time.  
 
However, as with the natural extracts, native-life recombinant allergens pose 
similar risks of anaphylactic side effects. Therefore, allergens with reduced IgE 
binding, called hypoallergens, have been proposed to improve safety of 
immunotherapy. Approaches to the generation of hypoallergens include site-directed 
mutations of known IgE binding epitopes and the destruction of three dimensional 
protein conformation by disrupting disulphide bonds, fragmentation of proteins or 
through the use of peptides (Gafvelin et al., 2007).  
 
In the constant search for vaccines to address existing problems and improve 
efficacy and safety, combinatorial hybrid molecules have been explored as potential 
vaccines for allergy.  
 
1.4.3.1 Hybrids 
Some allergen sources such as birch pollen and cat dander contain a single 
major allergen that includes most of the disease-eliciting epitopes (Linhart and Valenta, 
2004). Immunotherapy against these sources would essentially require only the major 
allergen as vaccine. However, most other allergen sources such as dust mite contain 
several allergens that may not be immunologically related. Further, allergic patients are 
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frequently sensitized to more than one allergen from a source (Silvestri et al., 1996; 
Cuerra et al., 1998; Linhart and Valenta, 2004), therefore it would be necessary to 
vaccinate simultaneously against several allergens from the source.   
 
Hybrids are suitable for vaccination against these complex sources. They are 
fusion proteins that consist of two or more allergens or the derivatives that have been 
combined via genetic engineering. The cDNA encoding the individual components are 
assembled together by polymerase chain reaction (PCR) and the resultant constructs are 
expressed as a single recombinant protein.  
 
As recombinant proteins, hybrid allergens can be expressed and purified in 
defined composition. This eliminates problems of new sensitizations or 
under-representation of allergens, associated with natural extracts. Although a 
recombinant cocktail vaccine containing a mixture of uncombined recombinant 
allergens could similarly offer the same benefits, it overlooks the problem that some 
allergens or derivatives exhibit poor immunogenicity. In contrast, the fusion of poorly 
immunogenic allergens with allergens from the same source in a hybrid had been 
shown to strongly enhance the immunogenicity of the low immunogenic molecules 
(Linhart and Valenta, 2005).  
 
To date, hybrid allergens have been constructed for allergens involved in grass 
and weed pollen, wasp and bee venom associated allergies (Table 2). Although not 
 26 
clinically tested as yet, the hybrids studied thus far have demonstrated to be potential 





Species Molecule/ Peptide* Reference 





Ves v 5 + Pol a 5 King et al., 2001 
    
Bee 
Venom 
Apis mellifera Ap1 m 1 + Api m 2 Kussebi et al., 2005 
    
Phleum pratense Phl p 2 + Phl p 6;  
Phl p 6 + Phl p 2;  
Phl p 5 + Phl p 1 
Linhart et al., 2002 Grass 
Pollen 
 Phl p 6 + Phl p 2 +  
Phl p 5 + Phl p 1 
Linhart et al., 2005 
    
Parietaria judaica Par j 2 + Par j 1 Bonura et al., 2007 Weed 
Pollen  Par j 1 + Par j 2; González-Rioja et al., 
2007 
    
* Hybrid comprising allergens or its modified derivatives 
Table 2. Summary of hybrids of allergens previously studied.  
 
1.5 Aims and Objectives 
The hybrid approach could be similarly applied to other allergen sources, such 
as dust mite, the most important indoor allergen source. This study aims to construct 
hybrids comprising important allergens of house dust mite Dermatophagoides 
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pteronyssinus and to evaluate their potential as potential vaccines for 
immunotherapy.  
 
1.5.1 Selection of allergens from Dermatophagoides pteronyssinus for 
incorporation into hybrids 
Owing, in part, to the difficulties involved in producing a hybrid consisting of 
all allergens from a source, the incorporation of only a few selected, important allergens 
that affect a large proportion of the population into hybrids should suffice to generate a 
vaccine effective for most sensitized patients.  
 
The two most important major allergens from D. pteronyssinus are Der p 1 and 
Der p 2. In many populations tested, more than 80% of mite-allergic patients are 
sensitized to Der p 1 (van der Zee et al., 1988; Krilis et al., 1984) and 70-88% are 
sensitized to Der p 2 (Lynch et al., 1997; Shen et al., 1996). Der p 1- and Der p 
2-specific IgE frequently accounted for more than 50% of total serum IgE against the 
whole mite extract (van der Zee et al., 1988; Lynch et al., 1997). Immunoblot studies 
with local mite-allergic patients further highlighted the importance of these two 
allergens, with frequencies of sensitization at 87.8% for Der p 1 and 78% for Der p 2 
(Unpublished data).  
Der p 5 and Der p 7 represent the two other important allergens, where the 
frequencies of sensitization range from 50-77.4% for Der p 5 and approximate 52-53% 
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for Der p 7 (Shen et al., 1993; Lin et al., 1994; Lynch et al, 1996; Kuo et al., 2003). 
Specific IgE to these two allergens accounted for 20-25% of total IgE against mite 
extract (Lynch et al., 1996). Of note, although the frequency of sensitization to Der p 7 
may be lower than Der p 2, its specific IgE binding was observed to be equally high, if 
not higher than that with Der p 2 in a large percentage of subjects, indicating the 
importance of this allergen (Shen et al., 1996).  
 
With considerations of their importance in terms of frequency of sensitizations 
in studied populations, Der p 1, Der p 2, Der p 5 and Der p 7 were selected to be 
incorporated into hybrids that could potentially act as vaccines for immunotherapy 
against these allergens.  
2 Materials and Methods 
2.1 Genetic engineering of hybrid constructs 
2.1.1 Bacteria host strains for transformation 
Strain Genotype 
  
XL1-Blue [N1] Δ(mcrA) 183Δ(mcrCB-hsdSMR-mrr)173 
end A1 supE44 thi-1 recA1 gyr 1A96 relA1 








Table 3. Strains of Escherichia coli used in study.  
 29 
2.1.2 Polymerase chain reaction – based molecular cloning 
Plasmids expressing Der p 1-2 and Der p 7-5 were constructed from cDNAs 
clones that code for the mature proteins of Der p 1, Der p 2, Der 5 and Der p 7. Forward 
and reverse primers (Research Biolabs, Singapore) as shown in Table 4 were used to 
amplify the plasmids using high fidelity KOD XL DNA polymerase (Novagen, 
Madison Wisc., USA). The coding region of Der p 2 and Der p 5 clones were amplified 
using DP2F-DP2R and DP5F-DP5R forward and reverse primer pairs. The clones of 
Der p 1 and Der p 7 were amplified using AFTF-DP1R and AFTF-DP7R forward and 













Table 4. Primers used in the cloning of hybrid constructs. 
 
Each of the reactions were carried out in a 50 µl mixture comprising of 2.5 ng 
recombinant plasmids, 0.2 nM dNTPs, 0.4 µM forward primer, 0.4 µM reverse primer, 
10 times PCR buffer and 2.5U KOD XL DNA polymerase.  
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Thermocycling was carried out in PTC-100™ Programmable Thermal 
Controller (MJ Research Inc., USA). For the amplification of the coding regions of the 
allergens, profile was set as follows: denaturation at 94°C for 30 seconds, annealing at 
50°C for 20 seconds and extension at 74°C for 2 minutes and repeated for 32 cycles. 
Extension time was 8 minutes for the amplification along the entire length of plasmid.  
 
Amplified products of Der p 2 and Der p 5 were subjected to kinase reaction 
with 1 µl T4 polynucleotide kinase (Research Biolabs, Singapore), 4 µl 10 times kinase 
buffer and 1 µl ATP in a 40 µl reaction mixture, for one hour at 37°C. Products Der p 1 
and Der p 7 amplification were incubated with restriction enzyme Dpn I (Stratagene, 
USA) in 10 times Dpn I reaction buffer and left to stand for an hour at 37°C. Thereafter, 
products were purified using the QIAquick PCR purification kit (Qiagen Inc., USA), 
following manufacturer’s manual.  
 
2.1.3 Ligation and transformation into Escherichia coli XL1-Blue   
The purified products were ligated using T4 DNA ligase in 10 µl reaction 
mixture containing the 2 times T4 DNA ligase buffer and topped up with deionised 
water. Reaction mixture was left to stand for 4 hours at 37°C. Subsequently, 2µl of the 
ligation product was added to 100µl of XL1-Blue competent cells, mixed and placed on 
ice for 40 minutes, incubated at 42º C for 1.5 minutes and cooled on ice again for 5 
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minutes. Transformed cells were then allowed to grow in 1ml Luria-Bertani (LB) 
medium for 45 minutes at 37ºC with shaking. Following incubation, the cells were then 
plated on gels containing LB and 100 µg/ml ampicillin.  
 
Colonies from the agar plats were picked and inoculated into liquid LB medium 
that containing ampicillin. The culture was allowed to grow overnight at 37ºC. The 
plasmids were extracted using the QIAprep Spin Miniprep Kit (Qiagen Inc., USA) and 
sequenced in both forward and reverse directions.  
 
2.1.4 Automated DNA Sequencing 
DNA sequencing was performed as suggested in Prism™ cycle sequencing kits 
(Perkin Elmer, USA) using a 20µl reaction mixture of 2 µl terminator ready reaction 
mix, 250 ng DNA templates and 10 pmole forward or reverse primers. Thermocycling 
profile was set for denaturation at 96° C for 30 seconds, annealing at 50° C for 15 
seconds, extension at 60° C for 4 minutes and repeated for 29 cycles.  
 
After cycle sequencing, 3 µl of 3 M sodium acetate (pH 4.6), 62.5 µl of 95% 
ethanol and 14.5 µl deionised water were added to reaction mixture and incubated at 
room temperature for 5 minutes. Thereafter, precipitated DNA was subjected to 
centrifugation at 13 000 g for 21 minutes. DNA pellet was washed with 500 µl of 70% 
ethanol. Centrifugation was performed for another 5 minutes and the supernatant was 
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removed by pipetting. Finally, the pellet was air-dried before DNA sequence analysis 
on ABI Prism 377 DNA sequencer. Sequencing gel fraction services were provided by 
DNA Sequencing Laboratory, Department of Biological Sciences, NUS. 
 
2.2 Protein Expression and Purification 
2.2.1 Transformation into Escherichia coli BL21(DE3) 
Recombinant plasmids coding for hybrids Der p 1-2, Der p 7-5 and the 
individual allergens Der p 1, Der p 2, Der p 5 and Der p 7 were first transformed into 
Escherichia coli BL21 (DE3) (Novagen, Madison Wisc., USA) as described earlier. 
This strain of E. coli lacks the Ion protease and the ompT outer membrane protease that 
can degrade proteins during purification (Grodberg and Dunn, 1988) and is a 
commonly used host for gene expression. 
 
2.2.2 Induction and expression of proteins 
A single colony was picked from the plate and inoculated into 2 ml LB liquid 
medium containing ampicillin and grown overnight at 37°C with shaking (230 rpm). 
The culture was then transferred to a 200 ml fresh medium with ampillin and cultured at 
37°C with shaking (230 rpm), until the OD600 reaches 0.6. Expression was induced by 
the addition of 1 mM isopropyl 1-thio-β-D-galactoside (IPTG) for 4 hours at 37°C with 
shaking (230 rpm). At the end of protein induction, cells were harvested by 
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centrifugation at 3,500 rpm for 5 minutes at 4°C. Cell pellets were kept at -20°C. until 
ready for purification.  
 
2.2.3 Protein Purification 
Der p 5 and Der p 7 were purified in non-denaturing conditions while 
recombinant allergens Der p 1, Der p 2 and D. pteronyssinus hybrid proteins Der p 1-2 
and Der p 7-5 were purified in the presence of 8M urea denaturant.   
 
2.2.3.1 Protein purification under non-denaturing conditions 
Cell pellets from the 200 ml cultures were resuspended in 50 ml of Nickel 
binding buffer (0.5 M NaCl, 5 mM Immidazole and 20 mM Tris-Cl, pH 7.9). The 
suspension was divided into 2 tubes and sonicated on ice for 3 minute each at 38% 
sonication amplitude. Four rounds of sonication were carried out and then centrifuged 
for 30 minutes at 13,000 rpm at 4°C. The supernatant was incubated with charged 
Ni-NTA resin (Novagen) and washed with 10 times volume of wash buffer (0.5 M 
NaCl, 60 mM Immidazole, and 20 mM Tris-HCl, pH 7.9) to remove unbound proteins 
and finally eluted with elution buffer (300 mM imidazole, 0.5 M NaCl and 20 mM 
Tris-HCl, pH 7.9).  
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2.2.3.2 Protein purification under denaturing condition 
Cell pellets from the 200 ml cultures were resuspended in 40 ml of 1X nickel 
binding buffer (0.5 M NaCl, 5 mM Immidazole and 20 mM Tris-HCl, pH 7.9). The 
suspension was sonicated on ice for 3 minutes at 38% sonication amplitude. Four 
rounds of sonication were carried out. Suspension was centrifuged at 13,000 rpm for 20 
minutes at 4°C, the supernatant was decanted. The pellet was resuspended in fresh 
nickel binding buffer and centrifuged for a second time, to collect inclusion bodies and 
cellular debris. 10 ml of nickel binding buffer containing 8M urea was then added and 
the suspension was incubated on ice for an hour to solubilize proteins residing within 
inclusion bodies and centrifuged at 13,000 rpm for 20 minutes at 4°C. 
 
Cell lysate was incubated with charged Ni-NTA resin (Novagen) and washed 
with 10 times volume of wash buffer (0.5 M NaCl, 60 mM Immidazole, and 20 mM 
Tris-HCl, pH 7.9) with 8M urea to remove unbound proteins and finally eluted with 
elution buffer (300 mM imidazole, 0.5 M NaCl and 20 mM Tris-HCl, pH 7.9) 
containing 8M urea.  
 
2.2.4 Protein refolding 
Purified Der p 2 and Der p 7 were further refolded by rapid dilution and dialysis 
respectively. With the aid of a peristaltic pump, purified Der p 2 was dropped into 50 
mM sodium acetate, pH 4.6 at 4°C. The refolded protein was concentrated using 
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Amicon Stir Cell (Millipore) using a membrane with 3000 Da molecular weight cut off. 
Der p 7, on the other hand, was refolded by dialyzing it into PBS overnight at 4°C, 
using a SnakeskinT Dialysis Tubing (Pierce Biotechnology) with a molecular weight 
cut off of 3500 Da. 
 
2.2.5 Quantification of protein concentration 
Concentration of purified proteins was determined using Bio-Rad protein assay 
(Bio-rad Laboratories, CA, USA) as per manufacturer’s instructions using serially 
diluted bovine serum albumin (BSA) as standard. 
 
2.3 Human sera samples 
Consecutive serum samples from local patients showing clinical symptoms of 
allergies were used in this study. Approval to conduct the studies was obtained from the 
Institutional Review Board of the National Healthcare Group, KK Women’s and 
Children’s Hospital, and Singapore General Hospital.   
 
2.4 Immunization of rabbits 
 Groups of three New Zealand White rabbits (2.5 to 3 kg) were each immunized 
subcutaneously with 420 µg of purified hybrid proteins or the individual allergens 
recombinant Der p 1, Der p 5 or Der p 7 diluted in PBS to a volume of 700 µl, and 
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mixed well with an equal volume of Freund’s complete adjuvant (Sigma-Aldrich). 
Control rabbit was immunized with the protein buffer in which the hybrids were 
purified. Boosters were mixed with Freund’s incomplete adjuvant (Sigma-Aldrich) 
instead and given once every two weeks.  
  
 Before immunization, rabbits were first anaesthetized subcutaneously with 
ketamine and xylazine. Blood was drawn using an infusion set through the ears of the 
rabbits. Blood collected was kept at 4˚C overnight to permit clotting and subsequently 
centrifuged at 3,000x g for 20 minutes at 4˚C. Sera were collected from the supernatant 
and kept in -20˚C until further analysis. 
 
Animals were maintained in the Animal Holding Unit of the Faculty of 
Medicine, National University of Singapore, in accordance to the local guidelines.   
 
2.5 Mice Immunization 
Mouse immunization studies were performed using eight weeks old female 
BALB/c mice. Groups of four mice were immunized with 15 µg of affinity purified 
native Der p 1 (Indoor Biotechnologies) or purified recombinant Der p 1 mixed with 
1.25 mg/ml aluminium hydroxide gel (Sigma-Aldrich) once every two weeks via 
intra-peritoneal injections.  Two mice were similarly immunized with the same 
 37 
volume of the buffer in which recombinant Der p 1 was purified, again mixed with 1.25 
mg/ml aluminium hydroxide gel. All dilutions were made with PBS buffer.  
 
Before injection, mice were anaesthetized intra-peritoneally with a ketamine 
(75mg/kg) and medetomidine (1mg/kg) mixture. Following each immunization, blood 
was drawn from the mice via orbital bleeding. Thereafter, reversing anesthesia 
comprising antisedan (atipamezole hydrochloride) was administered to facilitate the 
recovery of the animal. Blood collected was kept at 4˚C overnight and subsequently 
centrifuged at 5,000 rpm for 25 minutes at 4˚C. Sera were collected from the 
supernatant and kept in -20˚C until further analysis.   
 
Animals were maintained in the Animal Holding Unit of the Faculty of 
Medicine, National University of Singapore, in accordance to the local guidelines.   
 
2.6 Immunological studies 
2.6.1 Inhibition ELISA  
Sensitized human sera were pre-adsorbed overnight at 4˚C with serially diluted 
allergens nDer p 1, Der p 2, Der p 5, Der p 7, Der p 1-2, Der p 7-5 or with BSA as 
negative control. ELISA plates were coated with 250ng per well of the individual 
allergens, nDer p 1, Der p 2, Der p 5 or Der p 7 at 4˚C overnight.  
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The plates were washed and blocked using 0.1% PBS-Tween 20. 50 µl of the 
pre-incubated human sera were added to each well and incubated at 4˚C overnight. IgE 
binding of the human sera to the ELISA plate coated antigens was detected on the 
following day by incubating with biotinylated anti-human IgE monoclonal antibody 
(1:250 v/v in PBS) for 2 hours at room temperature, followed by avidin-alkaline 
phosphatase (1:1000 v/v in PBS). Microtiter plates were washed with 0.05% PBS-T 
between each step. Finally, 100 µl of 4-Nitrophenyl phosphate disodium salt dissolved 
in alkaline phosphatase buffer was added as substrate and absorbance measurements 
were read at 405 nm. Percentage inhibition of IgE binding to each of the allergens was 
calculated as follows, relative the negative control BSA: Percentage of inhibition of IgE 
binding = 100 – (ODA / ODBSA) X 100. ODA and ODBSA represent the optical density 
after pre-incubation with allergens and BSA, respectively.  
 
2.6.2 ELISA for the quantification of serum specific IgG 
Rabbit or mice IgG responses against their immunogens were determined using 
direct ELISA. The binding of IgG antibodies to individual allergens nDer p 1, Der p 2, 
Der p 5 or Der p 7 were determined using the same assay. Antigens were coated at 250 
ng per well onto Maxisorp plates (NUNC, Denmark) at 4˚C overnight. The plates were 
blocked with 0.1% PBS-Tween 20 for one hour at room temperature. Rabbit or mice 
antisera were serially diluted in PBS and incubated with the coated antigens for 2.5 
hours at room temperature. Bound rabbit and mice IgG antibodies were detected using 
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alkaline phosphatase conjugated anti-rabbit IgG and anti-mouse IgG antibodies, 
respectitvely. Microtiter plates were washed with 0.05% PBS-Tween 20 between each 
step. 4-Nitrophenyl phosphate disodium salt dissolved in alkaline phosphatase buffer 
was added as substrate and absorbance measurements were read at 405 nm.  
 
2.6.3 Inhibition of human IgE binding by specific IgG antibodies 
Allergens native Der p 1 (Indoor Biotechnologies) or purified recombinant Der 
p 2, Der p 5 and Der p 7 were coated at 250 ng per well onto Maxisorp ELISA plates 
(NUNC, Denmark) at 4˚C overnight. Plates were blocked with 0.1% PBS-T for 1 hour 
at room temperature the following day and incubated with 100 µl of rabbit or mouse 
serum serially diluted in PBS for 2.5 hours at room temperature. 50 µl of PBS-diluted 
human sera was then added to the wells and incubated at 4˚C overnight. 
 
Human IgE bound to the coated allergens were detected by incubating with 
biotinylated anti-human IgE monoclonal antibody (BD-Pharmingen, USA) (1:250 v/v 
in PBS) for 2 hours, and then with avidin conjugated alkaline phosphatase (1:1000 v/v 
in PBS) for another 30 minutes. Microtiter plates were washed with 0.05% PBS-T 
between each step. 4-Nitrophenyl phosphate disodium salt dissolved in alkaline 
phosphatase buffer was added as substrate and absorbance measurements were read at 
405 nm.  
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All experiments were carried out in duplicates and results were reported as 
mean values.  Percentage of inhibition of human IgE binding was determined with the 
following formula: % inhibition of IgE binding = 100 – (ODI/ODC) X 100, where ODI 
represents the absorbance value after pre-incubation with serum from immunized rabbit 
or mouse sera and ODC represents that of control respectively. 
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3  Results 
3.1 Genetic engineering of hybrids containing the major mite 
allergens of Dermatophagoides pteronyssinus  
As Der p 1, Der p 2, Der p 5 and Der p 7 were determined to be the important 
allergens of Dermatophagoides pteronyssinus, the cDNA clones of the individual 
allergens in pET32 vectors (5917 bp) were used to engineer hybrids comprising them. 
These clones were derived previously using the Expressed Sequence Tag (EST 
approach. A cDNA library generated for D. pteronyssinus was sequenced for 
identification of allergens through homology searches (Table 5). All sequences 
returned alignments with 99-100% sequence identity with published sequences of D. 
pteronyssinus allergens.  
 
Allergen Accession No % Identity (E-value) Reference 
    
Der p 1 P08176 100% (0.0) Chua et al., 1993 
Der p 2 P49278 100% (1e-79) Chua et al., 1990 
Der p 5 P14004 100% (4e-69) Lin et al., 1994 
Der p 7 P49273 100% (2e-120) Shen et al., 1993 
    
 
Table 5. Sequence homology of cDNA clones to published allergen sequences. 
Sequences of clones encoding cDNA of Der p 1, Der p 2, Der p 5 and Der p 7 were 
searched against a non-redundant protein sequence database at the site for the National 
Center for Biotechnology Information (NCBI). Amongst the returned result, only the 
highest scoring alignment with the lowest expectation value score is shown with the 
corresponding accession number of the published sequence.  
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Clones identified to encode allergens were then sub-cloned into pET32 vectors 
with the signal peptides, as predicted using SignalP software (SignalP 3.0, Center for 
Biological Sequence Analysis, TUD), deleted from the open reading frames. These 
were then used for the construction of the hybrids. A schematic diagram showing the 





Figure 2. Genetic engineering of hybrids containing the major mite allergens of 
Dermatophagoides pteronyssinus. The cDNAs of allergens Der p 1, Der p 2, Der p 5 
and Der p 7 were genetically combined, two at a time, into a hybrid construct. Allergen 
A and Allergen B denote any two allergens involved in each combination.  PNK, 
















Combining two allergens at a time, a long range DNA polymerase was used to 
amplify the cDNA sequence encoding one allergen (Allergen A). The cDNA clone of 
another (Allergen B) was linearized by amplifying the entire length of the plasmid 
(Figure 2), with the deletion of its stop codon during the amplification.  
 
Polynucleotide kinase incorporated an inorganic phosphate to the 5’ ends of the 
PCR products of amplified allergen A to allow for ligation subsequently. This, 
however, was not done to the linearized allergen B plasmid to prevent its re-ligation 
into the original cDNA clone, which, when transformed into competent cells, would 
grow on the selective media alongside cells transformed with successfully constructed 
hybrids. Instead, restriction exonuclease DpnI was added to the PCR products of 
allergen B to digest the parental plasmids, as the intact plasmids have enhanced 
transformation efficiency and may therefore potentially reduce the transformation of 
successfully ligated hybrids.  
 
Following their respective treatment with PNK and DpnI, products from PCR 
amplification of allergen A and allergen B were purified, ligated, transformed into 
Escherichia coli (XL1-Blue strain) competent cells and grown on selective media 
containing ampicillin. 
 
Colonies obtained following transformation were inoculated into liquid media 
and the plasmids were extracted thereafter (Figure 3). The open reading frames of the 
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hybrids were sequenced to ensure that the component allergens had been linked 
together in the right reading frame. Two successfully ligated hybrids were obtained, 
Der p 1-2 and Der p 7-5. Der p 1-2 had a length of 1320 bp while Der p 7-5 was 960 bp. 




Figure 3. Two successfully engineered hybrid constructs, Der p 1-2 and Der p 7-5.  
Extracted plasmids of Der p 1-2 and Der p 7-5 were extracted and subsequently 
sequenced. Der p 1-2 had a length of 1320 bp while Der p 7-5 was 960 bp. 
Consequently, the estimated sizes of their plasmids were approximately 7.2 kbp and 6.8 





Der p 1-2 Der p 7-5 Marker 
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3.2 Expression and purification of hybrids in Escherichia coli (BL21 
strain).  
3.2.1 Expression and purification of Der p 1-2 
Der p 1-2 was a 439 amino-acid long peptide that contained a six-histidine 
protein purification tag at the N terminal, followed by the mature Der p 1 sequence and 
mature Der p 2 (Figure 4A). It had a theoretical isoelectric point (pI) of 6.02 and a 
predicted molecular weight of 49316.42 Da (ExPASy proteomics server, Swiss 
Institute of Bioinformatics).  
 
 
   1 MDHHHHHHRP SSIKTFEEYK 20 
  21 KAFNKSYATF EDEEAARKNF 40 
  41 LESVKYVQSN GGAINHLSDL 60 
  61 SLDEFKNRFL MSAEAFEHLK 80 
  81 TQFDLNAETN ACSINGNAPA 100 
 101 EIDLRQMRTV TPIRMQGGCG 120 
 121 SCWAFSGVAA TESAYLAYRN 140 
 141 QSLDLAEQEL VDCASQHGCH 160 
 161 GDTIPRGIEY IQHNGVVQES 180 
 181 YYRYVAREQS CRRPNAQRFG 200 
 201 ISNYCQIYPP NVNKIREALA 220 
 221 QTHSAIAVII GIKDLDAFRH 240 
 241 YDGRTIIQRD NGYQPNYHAV 260 
 261 NIVGYSNAQG VDYWIVRNSW 280 
 281 DTNWGDNGYG YFAANIDLMM 300 
 301 IEEYPYVVIL DQVDVKDCAN 320 
 321 HEIKKVLVPG CHGSEPCIIH 340 
 341 RGKPFQLEAV FEANQNTKTA 360 
 361 KIEIKASIDG LEVDVPGIDP 380 
 381 NACHYMKCPL VKGQQYDIKY 400 
 401 TWNVPKIAPK SENVVVTVKV 420 




Figure 4. Expression of Der p 1-2. (A) 
Successfully cloned Der p 1-2 contained 
a six-histidine purification tag, the 
mature Der p 1 protein (green) and 
mature Der p 2 (blue). The construct 
was transformed and expressed in E. 
coli (BL21); and (B) purified in 0M 
urea (lane 2), 4M urea (lane 3) and 8M 
(lane 4). Marker (lane 1). 
B. A. 
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Der p 1-2 was expressed with low yield under non-denaturing conditions 
(Figure 4B). However, increasing the concentration of the urea denaturant increased the 
yield correspondingly. The observed molecular weight of Der p 1-2 on SDS-PAGE is 
approximately 45 kDa.  
3.2.2 Expression and purification of Der p 7-5 
Der p 7-5 was a 319 amino-acid long peptide that contained a six-histidine 
purification tag at the N terminal, followed by mature Der p 7 sequence and then the 
mature Der p 5 (Figure 5A). Its theoretical isoelectric point (pI) was 5.18 and the 
molecular weight was predicted to be 36817.00 Da (ExPASy proteomics server, Swiss 
Institute of Bioinformatics). Like Der p 1-2, expressed Der p 7-5 was contained mainly 
within inclusion bodies. It had an observed molecular weight of slightly less than 45 
kDa on SDS-PAGE (Figure 5B).  
 
   1 MDHHHHHHDP IHYDKITEEI 20 
  21 NKAVDEAVAA IEKSETFDPM 40 
  41 KVPDHSDKFE RHIGIIDLKG 60 
  61 ELDMRNIQVR GLKQMKRVGD 80 
  81 ANVKSEDGVV KAHLLVGVHD 100 
 101 DVVSMEYDLA YKLGDLHPNT 120 
 121 HVISDIQDFV VELSLEVSEE 140 
 141 GNMTLTSFEV RQFANVVNHI 160 
 161 GGLSILDPIF AVLSDVLTAI 180 
 181 FQDTVRAEMT KVLAPAFKKE 200 
 201 LERNNQEDKK HDYQNEFDFL 220 
 221 LMERIHEQIK KGELALFYLQ 240 
 241 EQINHFEEKP TKEMKDKIVA 260 
 261 EMDTIIAMID GVRGVLDRLM 280 
 281 QRKDLDIFEQ YNLEMAKKSG 300 
 301 DILERDLKKE EARVKKIEV* 319 
 
Figure 5. Expression of Der p 7-5. (A) 
Der p 7-5 contained a His-purification 
tag, Der p 7 (red) and Der p 5 (brown). 
The construct was transformed and 
expressed in E. coli (BL21); and (B) 





3.3 Hybrids have reduced IgE binding  
To evaluate the IgE binding capacities of the hybrids, the hybrids were 
pre-incubated in various concentrations with human sera that had been shown to be 
sensitized to the individual Der p 1, Der p 2, Der p 5 and Der p 7 allergens, before 
allowing the human sera to bind to the individual allergens coated on ELISA plates. 
Levels of human IgE bound onto the coated allergens were then measured.  
 
Hybrid proteins that bound human IgE act as inhibitors, reducing the level of 
unbound IgE that could therefore bind to the coated allergens. Consequently, levels of 
inhibition reflect the IgE binding capacities. The percentages of inhibition were 
calculated relative to a non-binding negative protein control, BSA, to eliminate the 
effects of steric hindrance. Percentages of inhibition obtained with Der p 1-2 or Der p 
7-5 as the inhibitor were compared to that with the individual allergens performed in 
the same assay. 
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Inhibition of Human IgE binding to Der p 5



































Figure 6. Inhibition of human IgE binding to allergens by hybrid proteins. ELISA 
inhibition assays were performed where human sera sensitized to Der p 1, Der p 2, Der 
p 5 or Der p 7 were preincubated with various concentration of hybrids or allergens 
(self) or BSA (negative control) as inhibitors, before being tested for the level of 
allergen-specific IgE. Levels of inhibition were expressed as percentages relative to 
negative control BSA. A representative inhibition curve for all four assays is shown.  
 
 
Typically, high levels of inhibition can be obtained at a low concentration of the 
self inhibitor (individual allergen) (Figure 6). On the other hand, a higher concentration 
of hybrids was needed to observe a small increase in the percentage inhibition. For 
instance, 0.25 µg/ml of Der p 7-5 was needed to elicit an inhibition of 7%. In contrast, 
0.025 µg/ml of Der p 7 alone was able to cause an inhibition of 29%. A representative 
inhibition curve for all four assays is shown in Figure 6.  
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native Der p 1
















































Percentage Inhibition of the Binding of Human Serum IgE to
 
 
Figure 7. Comparison of the inhibition capacity of hybrid proteins Der p 1-2 and 
Der p 7-5. Hybrid proteins were tested for their abilities to inhibit the binding of human 
serum IgE to individual allergens Der p 1, Der p 2, Der p 5 and Der p 7, and compared 
to that of the individual allergens (as self inhibitors). Indirectly, this assay measures the 
IgE binding capacities of (A) Der p 1-2 and (B) Der p 7-5.  
 
 
In comparison to the individual allergens, Der p 1-2 inhibited the binding of 
human IgE to native Der p 1 by 13%, as opposed to 84% inhibition with self protein, 
native Der p 1 (Figure 7A). The hybrid hardly inhibited Der p 2 (0.3%), in contrast to 




In the inhibition of human IgE binding to Der p 5, hybrid Der p 7-5 exhibited 
reduced inhibition (7%) compared to the Der p 5 allergen (65%) (Figure 7B). Der p 7-5 
inhibited IgE binding to Der p 7 by 44% while Der p 7 inhibited to a level of 69%.  
 
Taken together, both hybrids Der p 1-2 and Der p 7-5 had reduced capacity to 
inhibit the binding of human IgE to their component allergens. Correspondingly, the 
implication was that both hybrids had lower IgE binding capacity to each of their 
component allergens.  
 
3.4 Hybrids Induce Blocking IgG antibodies 
3.4.1 Hybrids Der p 1-2 and Der p 7-5 Induce IgG response in Rabbits 
To determine if the hybrids were capable of inducing IgG responses in vivo, 
New Zealand White (NZW) rabbits were immunized with either Der p 1-2, Der p 7-5 or 
protein buffer (control) once every two weeks. Rabbit sera were collected during each 
immunization. The levels of hybrid-specific rabbit IgG was determined in an ELISA 
binding assay where diluted rabbit sera in various concentrations were incubated with 
the respective hybrids. Binding was detected using anti-rabbit IgG and the level of 
which was reflected in the optical density (OD) readings.  
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Induction of IgG response in DP12A following immunization
















Figure 8. Representative profile of IgG antibodies induction in rabbits with 
hybrid immunization. New Zealand White rabbits were immunized with Der p 1-2 or 
Der p 7-5 once every 2 weeks. Rabbit antisera was collected at every immunization and 
tested, in various dilutions, for binding to the respective immunogens, Der p 1-2 or Der 
p 7-5. Levels of rabbit IgG specific for the hybrids were determined using anti-rabbit 
IgG antibodies.  
 
 
Figure 8 shows the level of Der p 1-2 specific IgG in sera collected from one 
rabbit, DP12A, in response to immunization with hybrid Der p 1-2. IgG antibodies 
from sera collected following the first immunization, first and second booster injections 
bound to coated Der p 1-2 in a dose dependent manner. In contrast, no binding was 
detected with the pre-immunization sera.  
 
Comparing the levels of IgG between the sera collected at different times during 
the immunization scheme, Der p 1-2 specific IgG antibodies increased with each 
immunization or booster, until the second booster, which did not drastically increase 
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the level of IgG. At this point, the maximal inducible IgG response was considered to 
be achieved.  
 
Similar assays performed with sera from all other Der p 1-2 immunized or Der p 
7-5 immunized rabbits showed the same profile of IgG induction. In rabbits that were 
immunized with Der p 1-2, maximal IgG induction was attained following two 
immunizations. The second booster did not increase IgG levels drastically. For 
immunization with Der p 7-5, maximal induction was obtained after three doses. 
However, one of the Der p 7-5 immunized rabbits, DP75F, became sick following the 
first immunization and was culled after the first booster. All other rabbits were culled 
when the maximal inducible IgG was reached.  
 
The hybrid proteins had been injected into groups of three rabbits during the 
immunization. Disregarding the death of one rabbit from the Der p 1-2 group, the 
hybrid had induced IgG responses in both the remaining rabbits, DP12A and DP12B 
(Figure 9A). Similarly, Der p 7-5 induced IgG responses in all three rabbits that had 
been immunized with the hybrid (Figure 9B). 
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Binding of Der p 1-2 Induced









Rabbit Serum Concentration (v/v)
O
D
Binding of Der p 7-5 Induced



























Figure 9. Hybrids induced IgG antibodies in all immunized rabbits. (A) Two 
rabbits immunized with Der p 1-2 had IgG antibodies that bound to the hybrid coated 
on an ELISA plate. (B) Der p 7-5 also induced IgG responses in all three rabbits in the 
group.  
 
3.4.2 Hybrid-induced IgG binds to individual allergens 
 Hybrids induced rabbit IgG were tested for their ability to recognize the individual 
allergens of which the hybrids were composed. Rabbit antisera, diluted to varying 
extents, were incubated with the individual allergens coated into wells of an ELISA 
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Figure 10. Binding of Der p 1-2 induced IgG to individual allergens. Antisera from 
Der p 1-2 immunized rabbits, DP12A and DP12B, were tested in various dilutions for 
IgG binding to (A) native Der p 1 and (B) Der p 2.  
 
 
 The two rabbits that had been immunized with hybrid Der p 1-2, DP12A and 
DP12B, had IgG that bound to native Der p 1 in a dose dependent manner, reaching 
maximal binding titer at approximately 2% v/v rabbit serum level (Figure 10A). In 
contrast, control rabbit that had been immunized with the protein buffer that Der p 1-2 
was purified in did not exhibit any significant binding. Besides native Der p 1, the 
antisera from rabbits DP12A and DP12B also contained IgG antibodies that bound to 
the individual Der p 2 protein (Figure 10B). Control rabbit, however, did not bind have 
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Figure 11. Binding of Der p 7-5 induced IgG to individual allergens. Antisera from 
Der p 7-5 immunized rabbits, DP75D, DP75E and DP75F, were tested in various 
dilutions for IgG binding to (C) Der p 5 and (D) Der p 7.  Antisera from rabbits 
immunized with Der p 5 (DP5    «    ) and Der p 7 (DP7    ²    ) alone were included 
in the same assay for comparison.  
 
 
Antisera from the three Der p 7-5 immunized rabbits, DP75D, DP75E and 
DP75F were tested for binding to the component allergens Der p 5 and Der p 7 in an 
ELISA binding assay. For comparison purposes, two rabbits were immunized with the 
individual allergens, Der p 5 or Der p 7 alone, using the same immunization scheme as 
for hybrid Der p 7-5, where injections were given once every two weeks, until the 
maximal inducible IgG level was obtained. The rabbits were then culled and the 
antisera were similarly tested for binding to the allergens in the same assay.  
 
The IgG antibodies from DP75D, DP75E and DP75F were demonstrated to 




(v/v) increased, until a maximal binding titer was obtained at approximately 2% v/v. A 
similar binding profile was obtained with the IgG that was induced against Der p 5 
allergen alone.  
 
IgG antibodies from the same Der p 7-5 immunized rabbits bound to Der p 7 as 
well (Figure 11B). Maximal binding titer for DP75D and DP75E was about 2% v/v 
while that for DP75F was slightly higher at 8% v/v. Binding profile of the IgG induced 
by Der p 7 immunization was comparable to that of DP75F.  
 
3.4.3 Hybrid induced IgG inhibits the binding of human IgE to the 
individual allergens 
Having shown that hybrid-induced rabbit IgG could bind to component 
allergens of the corresponding hybrid (Figure 10 and 11), an inhibition assay was 
performed to further determine if the IgG could inhibit the binding of human IgE to the 
allergens. Briefly, allergens were coated onto ELISA plates and incubated with rabbit 
antisera in various dilutions. Following that, the plates were washed and thereafter 
incubated with human sera that had been tested to be positively sensitized to the 
specific allergens. Binding of human serum IgE to the allergens was then detected 
using anti-human IgE antibodies.  
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Evident from the binding assays performed earlier (Figure 10 and 11), 
unspecific binding of the antisera to coated allergens could occur at high antiserum 
levels (control serum). This could, in turn, sterically hinder the binding of human IgE to 
the coated allergens, thus resulting in apparent inhibition even in the absence of 
allergen-specific IgG. To eliminate the effects of unspecific steric hindrance, the level 
of inhibition obtained with each rabbit serum was expressed as a percentage relative to 
the control rabbit.  
 
 Each of the two rabbit antisera from immunization with Der p 1-2 inhibited the 
binding of IgE from human serum 1 to native Der p 1 up to a maximal inhibition level 
was achieved at about 63-71% (Figure 12A). The same antisera could also inhibit the 
binding of IgE from human serum 2 to correctly folded Der p 2 in a dose dependent 
manner (Figure 12B). However, percentages of inhibition obtained with the group two 
assay were only 29-49% at the higheset level of rabbit antiserum (v/v) tested.  
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Figure 12. Inhibition of human IgE binding to native Der p 1 and Der p 2 by Der p 
1-2 immunized rabbit antisera. Capacity of hybrid induced IgG to inhibit IgE binding 
to (A) native Der p 1 and (B) Der p 2 was tested in an inhibition ELISA assay using 
serial dilutions of the rabbit antisera. Percentages of inhibition were expressed relative 
to control rabbit. 
 
Antisera from all the three rabbits immunized with Der p 7-5 inhibited IgE 




concentration tested (10% v/v). At the same level of antiserum, Der p 5 immunized 
antiserum inhibited maximally at 76% (Figure 13A).  
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Figure 13. Inhibition of human IgE binding to Der p 5 and Der p 7 by Der p 7-5 
immunized rabbit antisera. Capacity of hybrid induced IgG to inhibit IgE binding to 
(A) Der p 5 and (B) Der p 7 was tested in an inhibition ELISA assay using serial 
dilutions of the rabbit antisera. Percentages of inhibition were expressed relative to 
control rabbit. Inhibitions due to IgG induced by individual allergens Der p 5 or Der p 7 





The same antisera inhibited IgE binding to Der p 7 in a dose dependent manner 
(Figure 13B). Limited by the volume of human sera available, the highest level of 
antisera concentration tested was 5% v/v. Nonetheless, Der p 7-5 immunized antisera 
inhibited by 86-92%, while that obtained with rabbit immunized with Der p 7 alone was 
87%.  
  
3.5 Comparison of individual Der p 1 and hybrid Der p 1-2 as 
potential vaccines 
To compare the effect of incorporating a single allergen into a hybrid, 
recombinant Der p 1, similarly expressed under denaturing conditions as with Der p 
1-2, was injected into a NZW rabbit once every two weeks, using the same 
immunization scheme as that for Der p 1-2.  
 
3.5.1 Recombinant Der p 1 induced IgG in rabbits that bound the native 
protein and blocked the binding of human IgE to the allergen. 
Immunization with recombinant Der p 1 induced IgG antibodies that could 
recognize and bind to the native protein in an ELISA assay, in contrast to that of control 
rabbit (Figure 14A). However, the IgG response was lower than that induced by 
immunization with Der p 1-2.  
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Figure 14. Comparison of IgG antibodies induced by recombinant Der p 1 and 
Der p 1-2. Rabbits immunized with the recombinant form of Der p 1 (   «   ) had 
induced IgG that could (A) bind to native Der p 1 and (B) inhibit the binding of human 
serum IgE to the allergen, in a dose dependent manner.  
 
Further, antiserum from Der p 1 immunized rabbit inhibited the binding of IgE 
from Der p 1-sensitized human serum in a dose dependent manner, albeit by a small 




3.5.2 IgG antibodies induced by recombinant Der p 1 had reduced IgE 
blocking capacity in contrast to IgG antibodies induced by hybrid 
Der p 1-2 
To validate if Der p 1 induced IgG antibodies consistently blocked IgE binding 
to a smaller extent as compared to the hybrid, an additional inhibition assay was 
performed with a different human serum and at the antiserum concentration where 
maximal inhibition was achieved (Figure 14B). The levels of inhibition obtained with 
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Figure 15. Comparison of Der p 1 and Der p 1-2 as immunogens for induction of 
blocking IgG. Der p 1 and Der p 1-2 were used to immunized NZW rabbits and the 
levels of inhibition obtained by the corresponding IgG induced were compared rabbit 
antiserum concentration of 5% v/v.  
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In both human sera tested, each of the rabbits immunized with Der p 1-2 
exhibited higher levels of inhibition as opposed to that achieved with Der p 1 alone. 
With human serum 1, Der p 1 immunized antiserum inhibited to 14% while Der p 1-2 
immunized antisera inhibited by 63-71%. In the assay performed with human serum 5, 
Der p 1 immunized antiserum failed to inhibit human IgE binding to native Der p 1. In 










At the same antiserum concentration where Der p 1 and Der p 1-2 showed 
distinct difference in their capacity to induce blocking IgG, the binding of IgG 
antibodies induced by both proteins to native Der p 1 was found to be comparable 
(Figure 16).  
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Figure 16. Binding of rabbit IgG to native 
Der p 1 at 0.05 v/v. 
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3.6 Importance of conformation on generation of allergy vaccine 
3.6.1 Recombinant Der p 1 induces IgG that bind to Native Protein 
To determine the importance of maintaining conformation in an allergy 
vaccine, groups of BALB/c mice were immunized once every two weeks with native 
Der p 1 (nDer p 1), recombinant Der p 1 (rDer p 1) expressed in denaturing conditions 
or with the protein buffer as control. All mice immunized with nDer p 1 and rDer p 1 
had IgG antibodies that bound to the native protein (Figure 17).  
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Figure 17. Induction of IgG in BALB/c mice following immunization with native 
Der p 1 and recombinant Der p 1. Groups of BALB/c mice were immunized once 
every two weeks with native Der p 1, recombinant Der p 1 expressed in denaturing 
conditions or protein buffer (control). Pre- and post-immunization mice sera were 
incubated, at various dilutions, with coated native Der p 1 on ELISA plates. Binding of 
mice IgG to the native protein was detected using anti-mice IgG antibodies. Figure 
shows a representative profile of mice from all three groups. OD readings reflect the 
extent of binding by mice IgG.  
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All sera collected from before the immunization did not exhibit binding at all 
tested levels of mice serum (Figure 17), suggesting that the binding activity observed 
was attributed to IgG  that had been induced in response to the immunization.  
 
3.6.2 Recombinant Der p 1 induced IgG inhibited the binding of human 
IgE to native Der p 1 
Dose Dependent Inhibition of the Binding

























Figure 18. Dose dependent inhibition of human IgE binding to native Der p 1 by 
mice antisera. Antisera of immunized mice were tested for the ability to inhibit the 
binding of human IgE to native Der p 1. Different concentrations (v/v) of mice sera 
were incubated with coated nDer p 1 before incubation with human serum. Finally 
bound human IgE was detected using anti-human IgE antibodies. Inhibition was 
expressed as a percentage relative to control rabbit.  
 
 
The ability of the induced IgG to inhibit the binding of human IgE to nDer p 1 
was tested in an inhibition ELISA assay. Percentages of inhibition were expressed 
relative to the control mice, to eliminate the effects steric hindrance. As seen from 
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Figure 18, all the antisera from nDer p 1 immunization (nDP1A, nDP1B, nDP1C) 
inhibited IgE binding to nDer p 1 by 39-73%, reaching maximal inhibition at mice 
antiserum concentration of approximately 8% v/v. Recombinant immunized mice 
antisera (rDP1A, rDP1B, rDP1C) similarly inhibited IgE in a dose dependent manner 
(Figure 18).  
 
3.6.3 IgG antibodies induced by recombinant Der p 1 showed reduced 
capacity to block IgE in comparison to IgG antibodies induced by 
native Der p 1 
To compare the levels of inhibition attained with both groups of mice, inhibition 
assays were performed with a total of three individual and one pooled human sera. As 
maximal inhibition was obtained at 8% v/v mice serum concentration (Figure 18), all 
the four assays were performed using mice serum at this concentration.  
 
Native-immunized mice antisera consistently displayed higher percentage of 
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Figure 19. Inhibition of the binding of human IgE to native Der p 1. Inhibition 
ELISA assays were performed at the same mice serum concentration (8% v/v) using 
three individual human sera and one pooled human sera. Levels of inhibition were 
expressed as a percentage of the control. Black bars (n) represent antisera of mice that 
had been immunized with native Der p 1. Unshaded bars (o) represent antisera from 
mice immunized with the recombinant.  
 
 68 
A binding assay performed at the mice serum concentration used for the 
inhibitions demonstrated that all native and recombinant induced IgG bound the nDer p 
1 at comparable levels (Figure 20).  
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Figure 20. Binding levels of mice sera at 8% v/v mice serum concentration.  
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4 Discussion 
4.1 Hybrids for house dust mite allergens of Dermatophagoides 
pteronyssinus 
Many allergen sources are complex, comprising several immunologically 
unrelated allergens. Often, patients are sensitized to more than one allergen from the 
source (Linhart and Valenta, 2004). Natural extracts allow for immunotherapy against 
all allergens to which patients are sensitized. However, the presence of other allergens 
in the extract had been shown to result in new sensitizations during the course of 
therapy (van Hage-Hamsten and Valenta, 2002). At the same time, as natural extracts 
have variable compositions, this may lead to under representation of allergens to which 
patients may be allergic. 
 
The combination of allergens into a single recombinant hybrid protein as 
allergy vaccine similarly allows for simultaneous therapy against allergies caused by 
several allergens. The capacity to be expressed and purified in defined composition, 
however, addresses the issues of allergen under-representation.  
 
Currently, the hybrid approach has only been studied in wasp and bee venom 
allergy and grass and weed pollen allergy (Table 2). This study aims to generate hybrids 
that combine allergens from house dust mite, Dermatophagoides pteronyssinus, a 
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clinically important allergy-causing mite species worldwide. It is unnecessary to 
include all allergens from the mite into the hybrids. Therefore, on the basis of high 
frequencies of sensitization, the major D. pteronyssinus allergens Der p 1, Der p 2, Der 
p 5 and Der p 7 were selected for incorporation. The cDNA clones were PCR-amplified 
and ligated in various ways to generate hybrids comprising of two allergens joined 
together.  
 
4.2 Genetic engineering of hybrids containing major mite allergens 
of Dermatophagoides pteronyssinus and expression in 
Escherichia coli 
cDNA clones encoding the individual allergens, mature Der p 1, Der p 2, Der p 
5 and Der p 7, were used in the genetic engineering of the D. pteronyssinus hybrids. 
They were previously generated using the expressed sequence tag (EST) approach and 
sub-cloned into pET32 vectors, during which signal peptides were deleted, ensuring the 
expression of only the mature form of the allergens, to which patients are exposed.  
 
The allergens were incorporated, two at a time, into the hybrids. The strategy 
employed in the genetic engineering of the hybrids utilized the polymerase chain 
reaction for the amplification of one allergen while linearizing another, before their 
ligation in a blunt end manner (Figure 2). In contrast to conventional restriction-type 
cloning, this approach bypassed the requirement for the presence of restriction sites at 
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the cDNA-vector sites in the clones; allows the allergens to be linked in series without 
the insertion of additional foreign amino acids between the allergens; and permitted the 
deletion of the stop codon at the 3’ end of the first allergen in the same step.  
 
In this study, two hybrids were successfully constructed.  Der p 1-2 was 
composed of Der p 1 and Der p 2 while Der p 7-5 comprised Der p 7 and Der p 5, in that 
order. No foreign amino acids were inserted in between the two components of the 
hybrids and a six-histidine protein purification tag in the N terminal facilitated protein 
purification using a Nickel column (Figure 4A and 5A). Although the construction of 
hybrids with the component allergens in the reverse order had been unsuccessful, 
Linhart et al. had demonstrated that the sequence of the allergens did not matter in the 
generation of hybrid vaccines for immunotherapy (Linhart et al., 2002).  
 
Both hybrids were expressed in E. coli (BL21) competent cells and found to be 
contained within inclusion bodies, despite adjustments such as lowering the culture 
temperature during induction. When purified in non-denaturing buffer, low yields of 
protein were obtained (Figure 4B). The yield, however, increased with the addition of 
increasing concentration of urea, a protein denaturant (Figure 4B), suggesting that the 
proteins were largely insoluble.  
 
However, lack of conformation does not render a protein incapable as a vaccine. 
In fact, fragments of cow dander allergen Bos d 2 (Zeiler et al., 1997), grass pollen 
 72 
allergen Bet v 1 (Vrtala et al., 1997; van Hage-Hamsten et al., 1999); and short 
synthetic peptides of Phl p 1 (Focke et al., 2001) and Phl p 7 (Westritschnig et al., 2004) 
had been proposed as vaccine candidates for immunotherapy, despite the apparent loss 
of three dimensional structure as detected from circular dichroism spectra. These 
peptides retained the capacity to stimulate allergen-specific T cells proliferation, as the 
linear T cell epitopes of the allergens were preserved independent of spatial 
conformation.  
 
Synthetic peptides of Phl p 1, Phl p 7 and two structural mutants of carrot 
allergen Dau c 1, Dau c 1.01 and Dau c 1.02 (Focke et al., 2001; Westritschnig et al., 
2004; Reese et al., 2007) were demonstrated to able to induce IgG antibodies in mice or 
rabbits which could inhibit the binding of patient serum IgE to the wildtype allergen.  
 
A consistent observation for all allergen derivatives with disrupted three 
dimensional structures was a reduction in allergenicity, whether measured in vitro by 
the determination of specific IgE levels, inhibition assays, histamine release, cell 
degranulation or in vivo using skin prick tests. Interestingly, the degree of 
conformational change elicited in dust mite allergen Der f 2 had been demonstrated to 
correlate with the degree of reduction in allergenic activities (Takai et al., 2000). 
 
As discussed, partial loss or even complete disruption of conformation may not 
diminish the capacity of an antigen to be a potential vaccine. Since the hybrids could 
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not be purified in significant yield unless under denaturing conditions, and in view of 
the above reasons, Der p 1-2 and Der p 7-5 were expressed in denaturing conditions in 
this study and assessed for their potential as vaccines for D. pteronyssinus-associated 
allergies.  
4.3 Evaluation of Der p 1-2 and Der p 7-5 as potential vaccines 
4.3.1 Hybrids Der p 1-2 and Der p 7-5 have reduced IgE binding 
One of the many shortcomings of natural extracts is the occurrence of side 
effects such as local or even systemic anaphylaxis during the immunotherapy as a result 
of the binding of administered vaccines to specific IgE in vivo during vaccination. To 
overcome this, hypoallergens have been proposed as vaccines instead. These modified 
allergens have reduced allergenicity and are unable to bind IgE in vivo, thus preventing 
the inflammatory side effects.  
 
As Gafvelin et al. correctly summarizes, strategies to generate hypoallergens 
broadly involve either site directed mutagenesis of B cell epitopes (Beezhold et al., 
2001; Swoboda et al., 2002 and Holm et al., 2004) or the disruption of the three 
dimensional structure of the allergen (Gafvelin et al., 2007). The former is a more 
straightforward approach. The B cell epitopes of an allergen are specific, antigenic sites 
on the protein that are recognized by B cell receptors or the corresponding IgE 
antibodies (van Regenmortel, 1996). Mutation of these sites serves to prevent the 
binding of human IgE to the allergens, hence generating a hypoallergen with reduced 
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allergenicity. However, this approach requires existing knowledge about the B cell 
epitopes of the allergen, which sometimes may not be available. For instance, of the 
four important D. pteronyssinus allergens, no literature has as yet done any epitope 
mapping for Der p 5 and Der p 7.  
 
Epitopes are classified as linear (continuous) or conformational 
(discontinuous), depending on whether the residues involved are contiguous in 
sequence or brought into spatial proximity by conformational protein folding (Stern, 
1991). The latter approach exerts the hypoallergenic effects more specifically through 
disruption of conformational B cell epitopes. In addition, since the primary structure of 
the allergens remains intact, thus linear T cell epitopes that are necessary for 
antigenicity are retained. The approach is particularly suitable for allergens where 
conformational epitopes predominate human IgE sensitization, like Der p 1 and Der p 
2, and where a detailed epitope map is not available.  
 
In this study, hybrids Der p 1-2 and Der p 7-5 had been expressed and purified 
under denaturing conditions and therefore presumed to have lost their overall three 
dimensional structures. To evaluate if they had reduced IgE binding activity as 
compared to the component allergens, inhibition assays as described in Section 2.6.1 
were performed.  
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It has to be noted that, as the hybrids comprised two allergens, the use of the 
inhibition assay was necessary in determining the level of IgE binding to each of the 
component allergens. In contrast, the use of direct IgE binding ELISA would be 
complicated by the possibility that the human sera contained IgE against both 
components or any other cross-reacting epitopes.  
 
Human sera that were tested to be sensitized to the allergens were allowed to 
bind to the allergens in the presence of inhibitors such as the individual allergens (self 
inhibition), the hybrid proteins and BSA (negative control). As the proteins had to bind 
to serum IgE in order to inhibit, the level of inhibition is an indirect measure of the IgE 
binding activity.  
 
The levels of inhibition obtained with the hybrid proteins were low but 
increased at high concentrations of the inhibitors (Figure 6). With the effects of steric 
hindrance eliminated through expression of the inhibition levels relative to the negative 
control BSA, the increasing levels of inhibition observed with increasing 
concentrations of hybrid inhibitors suggested that the hybrids contained some IgE 
epitopes that could be recognized by human serum IgE.   
 
However, at all doses tested, the levels of inhibition obtained with the hybrids 
were much reduced in comparison to that with individual allergens (Figure 6), 
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suggesting that the hybrids exhibited a still lower IgE binding capacity when compared 
to the individual allergens.  
 
From Figure 7A, Der p 1-2 had reduced IgE binding to native Der p 1 and Der p 
2 allergens. This was not unexpected because patients are known to be predominantly 
sensitized to the conformational epitopes of each of these allergens (Greene and 
Thomas, 1992; Collins et al., 1996; Chua et al., 1991; van’t Hof et al., 1991). Yet these 
epitopes were likely to have been disrupted as a result of the effects of the urea 
denaturant on overall three dimensional structure and of the convalent fusion to the 
allergen partner. In consequence, human IgE that are mainly targeted at conformational 
sites would be less likely to bind to the hybrids. In the same way, Der p 7-5 was shown 
to have reduced IgE binding to both Der p 5 and Der p 7, in comparison to the 
individual allergens (Figure 7B).  
 
Interestingly, in the inhibition of binding to Der p 7, the difference in inhibition 
levels between Der p 7 and Der p 7-5 was notably less pronounced, as compared to that 
observed in all three other assays with the other allergens (Figure 7B). A possible 
explanation could be that the human serum could have been sensitized to more linear 
epitopes, therefore, despite the loss of conformation, Der p 7-5 was able to bind to 
human IgE and inhibit its subsequent binding to coated allergens.  
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Nonetheless, Der p 1-2 and Der p 7-5 both exhibited reduced IgE binding in 
vitro in comparison to their component allergens, making them suitable hypoallergenic 
candidate vaccines for the immunotherapy for Der p 1 and Der p 2, and Der p 5 and Der 
p 7 respectively.  
 
4.3.2 Hybrids Der p 1-2 and Der p 7-5 induced IgG 
antibodies that bound to the individual allergens and 
inhibited the binding of human serum IgE to them 
In many studies, the ability to induce T cell proliferation and apparent reduction 
of in vitro or in vivo allergenicity were measures commonly used to access the potential 
of an allergen or its modified derivatives for use as allergy vaccines. However, while 
these measures promise the safety of the potential vaccine and ensure the feasibility of 
its use, they by no means warrant the efficacy of the candidates as vaccines.  
 
In this study, the capacity of hybrids to induce blocking IgG in vivo was 
included in addition to reduced allergenicity as the preliminary criteria to assess the 
hybrids as potentially efficacious vaccines.  
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4.3.2.1 Hybrids can induce IgG responses in vivo 
As potential vaccines, the hybrids should exhibit appropriate immunogenicity 
in vivo and be capable of raising antibodies (Stern, 1991). As seen from Figure 8, with 
each immunization of the hybrid proteins, the level of IgG antibodies recognizing the 
hybrid protein increased. Contrasted with the sera collected before immunization 
began, where hardly any IgG bound the coated hybrids, it is evident that the rabbits had 
no hybrid specific IgG antibodies prior to the immunization and therefore the hybrid 
specific IgG observed following the first immunization were responses induced by the 
immunization. 
 
Each hybrid was injected into a group of three rabbits. However, one rabbit 
from the Der p 1-2 group died following the first immunization. Nonetheless, Der p 1-2 
was demonstrated to induce IgG antibodies in both the remaining rabbits (Figure 9A). 
Similarly, Der p 7-5 induced IgG antibodies in all three immunized rabbits (Figure 9B). 
Of note, although DP75F became sick following the first immunization and was culled 
soon following the administration of the first booster, its IgG titer was comparable to 
that attained with the other two rabbits DP75D and DP75E, for which maximal IgG was 
attained after administration of the second booster. 
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4.3.2.2 Hybrid-induced IgG bound to individual component allergens  
It is believed that the protective effect of IgG antibodies induced during 
immunotherapy arises through direct competition with the sensitizing IgE antibodies 
for the allergens (Cooke et al., 1935; Loveless, 1940; Wachholz and Durham, 2004). 
The IgG would have to bind to the allergen in order to exert the blocking effect.  
 
To evaluate the potential efficacy of hybrids as vaccines that induce blocking 
IgG, it is therefore necessary to ensure that the IgG induced by the hybrids were able to 
bind to the individual allergens. In a direct ELISA binding assay, Der p 1-2 induced 
IgG were demonstrated to bind both native Der p 1 and Der p 2 in a dose dependent 
manner (Figure 10). In contrast, little binding was observed with the control rabbit. 
Similarly, Der p 7-5 immunized rabbits had IgG antibodies that bound to both Der p 5 
and Der p 7 allergens (Figure 11). It seemed, therefore, that polyclonal antibodies had 
been raised against the entire length of the hybrid peptide, with IgG antibodies 
recognizing both the component allergens.  
 
Further, the Der p 5-specific IgG responses induced by hybrid Der p 7-5 was 
shown to be comparable to that induced by Der p 5 alone (Figure 10). Likewise, IgG 
from the hybrid immunized antisera bound Der p 7 to similar extents as did the IgG 
raised from immunization with the individual allergen alone (Figure 11). These results 
suggested that Der p 7-5 possessed similar capacities as Der p 5 and Der p 7 to induce 
allergen-specific IgG in rabbits.  
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4.3.2.3 Hybrid-induced IgG blocks the binding of human IgE to 
individual allergens.  
While the induction of allergen-specific IgG is frequently observed with 
immunotherapy efficacy (Golden, 1982), the correlation is not without contend. 
Increased levels of allergen-specific IgG may sometimes not be observed with 
improved clinical outcomes (Ewan et al., 1993; Djurup et al., 1987). Moreover, there 
seems to be accumulating evidence that immunotherapy could alter antibody affinity 
and specificity (Till et al., 2004), both of which contribute to IgG blocking. Hence, it is 
important to measure the blocking activity, instead of the crude levels of 
allergen-specific IgG (Akdis and Akdis, 2007).  
 
Having established that the IgG antibodies induced by Der p 1-2 and Der p 7-5 
were able to bind to the component allergens of the respective hybrids, the capacity of 
these IgG antibodies to block the binding of IgE to the same allergens were tested in an 
inhibition ELISA assay. Antisera from the two rabbits immunized with Der p 1-2 were 
able to inhibit the binding of human IgE to both native Der p 1 and Der p 2 in a dose 
dependent manner (Figure 12). Similarly, each of the antisera from rabbits immunized 
with Der p 7-5 blocked IgE binding by at least 63% (Figure 13).  
 
As the hybrids had been expressed and purified under denaturing conditions, it 
was unlikely that the repertoire of IgG thus induced recognized conformational 
epitopes. The observed inhibition could instead be due to IgG antibodies binding to 
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linear epitopes situated along the lengths of the hybrid peptides, which would not have 
been disrupted by the lack of a global conformation.  
 
4.3.2.3.1 Blocking by Der p 1-2 induced IgG antibodies 
The levels of inhibition observed from the assay were dependent not only the 
induction of IgG antibodies in rabbits that bound the allergens, but also the type of 
epitopes against which the human IgE antibodies were sensitized.  
 
Both Der p 1 and Der p 2 are known to consist primarily of conformational IgE 
binding epitopes (Greene and Thomas, 1992; Collins et al., 1996; Chua et al., 1991; 
van’t Hof et al., 1991). It is therefore interesting that IgG induced by hybrid Der p 1-2 
inhibited binding to native Der p 1 up to a level as high as 63% (Figure 12). Besides 
blocking IgE that were targeted at linear epitopes, the binding of rabbit IgG to these 
sites could have sterically hindered the binding of other IgE targeted at conformational 
epitopes that are in close proximity. Additionally, there could be rabbit IgG induced 
against continuous regions on the hybrids that formed part of the conformational 
epitopes recognized by the human serum.  
 
Although Der p 1-2 immunized antisera could inhibit IgE binding to Der p 2, the 
level of inhibition was only 29-49% at the highest serum concentration tested. With 
consideration that Der p 1-2 IgG bound the allergen well in the direct binding assay 
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(Figure 10B), the lack of blocking could reflect a difference in the epitopes recognized 
by rabbit antibodies and that by human IgE. This could in part be due to genetic 
differences or altered antigen processing between the two hosts (Chapman et al., 1987); 
however, a more probably cause would be the disruption of conformational epitopes in 
the hybrid peptide to which most Der p 2-sensitized patient IgE are directed.  
Alternatively, differences in the affinities of rabbit IgG and human IgE for the same 
epitopes (Hantusch et al., 2005) could also have contributed to low levels of inhibition.  
4.3.2.3.2 Blocking by Der p 7-5 induced IgG antibodies 
Antisera from all three rabbits immunized with hybrid Der p 7-5 inhibited IgE 
binding to the component allergens Der p 5 and Der p 7, up to more than 80% (Figure 
13). This could be an indication that the predominant IgE binding epitopes are linear. 
To date, the nature of these epitopes has yet to be elucidated, although previous studies 
with the Der p 5 homolog from mite Blomia tropicalis, Blo t 5, suggested that patients 
react mainly to linear epitopes on mite group 5 allergens (Unpublished data).  
 
Nonetheless, Der p 7-5 was able to induce IgG in vivo which could inhibit IgE 
binding to both component allergens in vitro. In fact, the levels of inhibition achieved 
with hybrid-immunization were comparable if not higher than that obtained using the 
single allergens as the immunogens in rabbits (Figure 13). 
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4.3.2.4 Implications on the potential of Der p 1-2 and Der p 7-5 as 
vaccines 
Taken together, results from both the binding and inhibition assays suggested 
that hybrid Der p 7-5 was an appropriate immunogen that not only retained similar 
capacity as Der p 5 and Der p 7 alone for the in vivo induction of allergen specific IgG 
responses; beyond this, it probably retained the same IgG epitopes inducible by the 
individual allergens. Furthermore, Der p 7-5 had reduced IgE binding to human IgE in 
as compared to the individual counterparts. As such, Der p 7-5 is a suitable vaccine 
candidate for immunotherapy against allergies due to Der p 5 and Der p 7 at the same 
time.  
 
Der p 1-2 was demonstrated to exhibit reduced IgE binding and the capacity to 
induce blocking IgG antibodies to both its component allergens. Although the levels of 
inhibition obtained with Der p 2 was, as discussed, relatively lower compared to levels 
obtained with hybrid IgG against other allergens, additional studies should be 
performed to determine if this low level of IgE blocking is sufficient to inhibit the 
downstream IgE mediated allergic reactions.  
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4.4 Comparison of individual Der p 1 and hybrid Der p 1-2 as 
potential vaccines 
To enable a fair assessment of the effect of incorporating the allergen into a 
hybrid, the recombinant form of Der p 1 (rDer p 1) was expressed and purified under 
the same denaturing conditions as that for hybrid Der p 1-2. It was then injected into a 
NZW rabbit using the same immunization scheme as that for the hybrid.  
 
4.4.1 Incorporation of Der p 1 into hybrid Der p 1-2 increases its 
immunogenicity and induces a stronger IgG response 
IgG antibodies induced by rDer p 1 were demonstrated to bind the native 
allergen, nDer p 1 (Figure 14A). However the level of IgG responses specific to nDer p 
1 was much lower than that induced by hybrid Der p 1-2. It seemed, therefore, that the 
incorporation of Der p 1 into a larger fusion protein had increased its immunogenicity. 
A similar observation was made in a study on allergy vaccines of timothy grass pollen, 
where hybrids composed of two of the four major allergens induced stronger and earlier 
IgG responses in mice than individual allergens and even the whole allergen extract 
(Linhart et al., 2002).  
 
As with the pollen hybrids, this phenomenon could be explained by classical 
carrier effects. Der p 1 appears to have reduced immunogenicity compared to Der p 2 in 
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its capacity to induce IgG antibodies, as demonstrated in a recent pilot subcutaneous 
allergen-specific immunotherapy (SCIT) study on atopic dermatitis patients 
(Bussmann et al., 2007). It is believed that when a poorly immunogenic antigen, in this 
case Der p 1, is presented with a covalently linked, more immunogenic partner, Der p 2, 
T cell epitopes of the latter can enhance the immunogenicity of the former.  
 
While the complete understanding of this awaits further elucidation, that 
immunogenicity of Der p 1 was enhanced in Der p 1-2 demonstrated an important 
advantage of the hybrid vaccines over other types of allergy vaccines, corroborating 
findings from hybrid studies published previously (Linhart et al., 2002; Linhart et al., 
2005).  
 
4.4.2 Incorporation of Der p 1 into a hybrid widens the repertoire of the 
induced IgG 
Comparing the levels of inhibition elicited by immunization with either protein 
at 5% v/v rabbit antiserum concentration, each of the rabbits immunized with Der p 1-2 
consistently exhibited higher levels of inhibition as opposed to that achieved with Der p 
1 alone (Figure 15). 
 
Interestingly, results from the ELISA binding assay indicated that at the same 
rabbit antiserum concentration, IgG antibodies induced by Der p 1 bound the native 
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allergen as strongly as could that induced by the hybrid (Figure 16). It seemed 
therefore, that the difference in the levels of inhibition induced by the immunogens lay, 
not in the level of IgG bound to the allergen, but in the epitopes being recognized.  
 
Apart from those already recognized through immunization with Der p 1 alone, 
the incorporation of Der p 1 into a larger hybrid protein could have induced IgG that 
targeted additional antigenic epitopes, to which the human IgE also bound, hence 
leading to the apparent increase in the levels of inhibition. This observation is much 
akin to the phenomenon of epitope spreading, where the epitope specificity of 
immunological responses are diversified and increased to include more epitopes on the 
same molecule (Vanderlugt and Miller, 2002). Nonetheless, that the hybrid enhanced 
the repertoire of epitopes recognized by the IgG antibodies raised should expectedly 
improve the efficacy of hybrids for use as vaccines.  
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4.5 Maintaining conformation is important for allergy vaccines 
designed for allergens with predominantly conformational 
epitopes 
The data with Der p 7-5 had demonstrated that the unstructured hybrid could act 
as vaccine for Der p 5 and Der p 7 (Figure 8). However, the percentage inhibition of IgE 
binding to Der p 1 due to Der p 1-2 induced IgG was only up to 63%; while that for Der 
p 2 was also moderate at a mean of 33% inhibition.  
 
As discussed, the level of inhibition reflected was dependent on two factors, the 
type of epitopes that the human sera were sensitized to and the type of epitopes that the 
hybrids induced IgG recognized. With the knowledge that both Der p 1 and Der p 2 
consist mainly of conformational epitopes (Greene and Thomas, 1992; Collins et al., 
1996; Chua et al., 1991; van’t Hof et al., 1991), it seemed possible that the expression 
of hybrid Der p 1-2 under denaturing conditions could have led to the lack of IgG 
induced against conformational epitopes and consequently the moderate level of 
inhibition attained. 
 
To evaluate whether the lack of conformation had any significant impact on the 
ability to induce blocking IgG against allergens predominantly composed of 
conformational epitopes, BALB/c mice were immunized with either native Der p 1 
(nDer p 1) or recombinant Der p 1 (rDer p 1) that had been expressed and purified in the 
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same denaturing conditions as in the preceding section. The IgG antibodies induced in 
all native- and recombinant- immunized antisera were demonstrated to bind the native 
protein in an ELISA assay (Figure 17).  
 
 Inhibition assays were performed to determine if the antisera could, further, block 
the binding of human IgE to the allergen. Each of the native immunized antisera was 
able to inhibit IgE binding to nDer p 1; antisera from recombinant immunized mice 
similarly inhibited in a dose dependent inhibition (Figure 18).  
 
Der p 1 had previously been found to be denatured irreversibly by the protein 
denaturants, guanidine (6M) and urea (6M) (Lombardero et al., 1990). Therefore, it 
would be unlikely that the mice IgG repertoire induced by the recombinant protein in 
this study, expressed in an even higher concentration of the denaturant (8M urea), 
would recognize conformational epitopes on the allergen.  
 
As with the hybrids, the inhibition exhibited by mice antisera following 
immunization with the unstructured recombinant could be explained by the presence of 
linear epitopes on Der p 1, which could not have been disrupted by the presence of the 
urea denaturant. Binding of IgG antibodies induced against the linear regions of native 
Der p 1 in the inhibition assay could have directly blocked the binding of IgE directed 
against the very same sites, or sterically prevented IgE binding to regions in the 
vicinity.  
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However, the percentage of inhibition obtained with rDer p 1 immunization was 
consistently lower than that with nDer p 1 (Figure 19). Therefore, it seemed that the 
disruption of structure in the recombinant indeed had an effect on the ability to induce 
blocking IgG and consequently the potential as a vaccine.  
 
Additionally, IgG binding was comparable between the native- and 
recombinant- induced IgG antibodies at the level of mice serum that the inhibition 
assays were performed (Figure 20). Therefore, the reduced capacity of rDer p 
1-induced IgG to block IgE binding was attributable to genuine differences in the 
induced IgG repertoire, rather than differences in IgG titers. This further supported the 
possibility that the loss of conformation in the recombinant antigen affected the 
induction of blocking IgG antibodies by restricting the epitopes that repertoire of 
induced IgG could recognize.  
 
4.5.1 Importance of the conformation and implications on the generation 
of allergy vaccines 
Modification of the overall three dimensional structure of an allergen had been 
an effective strategy of obtaining allergy vaccine candidates by disrupting the IgE 
binding B cell epitopes and retaining the linear T cell epitopes, to reduce allergenicity 
and retain antigenicity, respectively (Smith and Chapman, 1996; Takai et al., 1997; 
Vrtala et al., 2001; Saarne et al., 2005). Amongst these studies, a number of them had 
 90 
also demonstrated that allergen derivatives with complete loss of overall conformation 
also retained the capacity to induce blocking IgG (Westritschnig et al., 2004; Focke et 
al., 2001; Reese et al., 2007).  
 
Similar observations were made in the evaluation of Der p 7-5 as a candidate 
vaccine. Despite expression in the presence of urea denaturant, the hybrid was able to 
induce IgG antibodies in all immunized rabbits that were able block the binding of 
human sera to the individual allergens by more than 80%.  
 
Reasonably, that allergen with disrupted conformation can induce IgG is not 
surprising. Linear epitopes are not affected by alterations in the three dimensional 
structure; any IgG induced against such regions would therefore be capable of blocking 
human IgE binding.  
 
However, this strategy is not as straight forward for allergens such as Der p 1. 
While the group one mite allergen had been shown to contain a few linear epitopes 
(Greene and Thomas, 1992), most human sera appeared to be sensitized to 
predominantly conformational epitopes of Der p 1 (Collins et al., 1996). The study with 
mice gave evidence that retaining the structure of the immunogen was important in the 
generation of blocking IgG antibodies. Yet, preservation of three dimensional structure 
prevents the reduction of allergenicity in such allergens where conformational epitopes 
are important (Reese et al., 2007).  
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Returning to the hybrids in this study, even with its conformation disrupted, Der 
p 1-2, induced IgG in rabbits that nonetheless blocked human serum IgE binding to 
native Der p 1 by up to 62%, comparable to levels achieved with nDer p 1 immunized 
mice antisera. Moreover, the inhibition percentages reflect only the capacity of the 
induced IgG to block IgE in vitro. It remains to be established whether the IgG are able 
to inhibit the downstream biological activities associated with IgE-mediated 
pathogenesis, such as degranulation of effector cells such as mast cells and basophils, 
release of inflammatory mediators, or IgE-mediated allergen presentation to T cells.  
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4.6  The hybrid approach – with perspectives from dust mite 
studies 
Most studies on hybrids of allergen had been done only in pollen and venom 
allergies. In this study, allergens from the clinically important house dust mite, 
Dermatophagoides pteronyssinus, had been used to study the applicability of the 
hybrid approach to mite allergies.  
 
4.6.1 Hybrids as suitable replacement for individual allergens as 
vaccines 
As a combinatorial vaccine, a hybrid should be able to act as effective vaccine 
for all its component allergens. In one of the pioneering studies that explored the use of 
allergen hybrids, Linhart et al. demonstrated that IgG antibodies that were raised 
against hybrids consisting of major grass pollen allergens were capable of inhibiting 
IgE binding to all the purified allergens (Linhart et al., 2002; Linhart et al., 2005). 
Similar results were obtained with the Parietaria weed pollen allergens (Bonura et al., 
2007).  
 
In this study with mite allergens, the hybrids constructed exhibited the capacity 
to induce IgG antibodies that inhibited the IgE binding to purified individual allergens 
in vitro. In particular, the inhibition levels achieved with Der p 7-5 was comparable to 
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that elicited by immunization with the individual allergens. This suggested that the 
hybrid could potentially replace Der p 5 and Der p 7 as vaccines to treat allergies to 
both allergens concurrently.  
 
4.6.2 Hybrids enhance immunogenicity  
Arguably, cocktail recombinant vaccines could similarly provide solution for 
multiple sensitization while negating the disadvantages attributed to undefined 
composition of natural extracts. However, their use does not take into account that 
some allergens (natural or recombinant as well as the modified derivatives) could be 
poorly immunogenic, such as the major mite allergen Der p 1 (Busmann et al., 2007).  
 
Grass pollen hybrids had been demonstrated to induce stronger and earlier 
specific IgG responses as compared to the single allergens or the total allergen extract 
(Linhart et al., 2002; Linhart et al., 2005). Furthermore, the hybrids elicited stronger 
lymphoproliferative responses than the individual allergens, equimolar mixture of all 
component allergens and the extract. With mite allergens, the incorporation of Der p 1 
into a hybrid molecule with Der p 2 initiated a stronger specific IgG response in NZW 
rabbits than when Der p 1 administered alone. The enhanced immunogenicity 
associated with hybrids could be attributed to the sheer increase in the molecular size of 
the immunogen or classical carrier effects. 
 
 94 
4.6.3 Hybrids enhance the repertoire of epitopes recognized by IgG 
induced by vaccine 
This study has further established that along with enhanced immunogenicity, 
presenting Der p 1 in a hybrid induced a repertoire of IgG antibodies that possibly 
directed at more epitopes in addition to those recognized by IgG induced with Der p 1 
alone, much akin to the phenomenon of epitope spreading. Indeed, this enhanced 
repertoire possibly contributed to the boost in the inhibition levels from 14% with Der p 
1 alone to 63-71% with the hybrid.  
 
4.6.4 Hybrids can be hypoallergenic 
Linhart et al. reported in their findings that hybrids of Phleum pretense retained 
most of the IgE binding epitopes and exhibited levels of allergenicity comparable to 
that with allergen extract (Linhart et al., 2002; Linhart et al., 2005).  
 
However, many others have demonstrated that it is possible to introduce 
hypoallergenicity into hybrids using similar strategies as those applied to individual 
recombinant allergens. Using variants of the allergens with deleted epitopes (King et 
al., 2001; González-Rioja et al., 2007) or mutations (Bonura et al., 2006), hybrids thus 
generated had reported reduction in IgE binding and allergenicity, both in vitro and in 
vivo. Similarly in this study, through expression under denaturing conditions, hybrids 
Der p 1-2 and Der p 7-5 were demonstrated to have reduced IgE binding capacities.  
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The reduced allergenicity discussed above not only renders the hybrids a safer 
vaccine in terms of reducing the risk of local and systemic anaphylactic reactions, it 
also allows for a higher dose of vaccine to be administered during immunotherapy. This 
could, in turn, favor allergen specific tolerance and suppression of IgE as well as permit 
an immunization scheme with reduced number of injections (Kussebi et al., 2005; 




Specific immunotherapy is the only curative therapy approach for the treatment 
of allergy. As exemplified by previous studies on venom and pollen allergen, and with 
mite allergens in this study, hybrids present a good alternative to existing forms of 
allergy vaccines.  
 
6 Future Work 
 In this study, it was demonstrated that hybrids comprising the major allergens 
from house dust mite Dermatophagoides pteronyssinus had reduced IgE binding 
capacity and induced blocking IgG in vivo. Succeeding this, further studies should be 
done to assess the ability of the induced IgG to block the biological effects mediated by 
IgE antibodies and to determine if immunization with the hybrids modulates T cell 
responses. Hypoallergenicity of the hybrids could be confirmed in allergenic 
individuals through skin prick tests or immunoblot studies using human serum samples. 
The hybrids in this study have demonstrated efficacy despite expression in denaturing 
conditions; however, it is recognized that for application as vaccines to be administered 
to human patients, alternatives to urea as denaturant should be explored.  
 
The insolubility of the vaccines remains an important caveat that needs to be 
addressed. Whilst Der p 1-2 has demonstrated potential as a hypoallergenic vaccine 
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nonetheless, observations from studies comparing the use of native Der p 1 and 
recombinant Der p1 as vaccine candidates (Section 4.5) highlighted the importance of 
retaining conformation in a vaccine; hence, it may be worthwhile to look into ways of 
increasing the solubility of the vaccines, such as through the introducing a soluble 
fusion peptide by means of genetic engineering to enhance overall solubility of the 
expressed product or explore other means of expression such as in vitro. Alternatively, 
dialysis or dilution against a suitable buffer may reduce the urea denaturant present and 
refold the hybrids into the native conformation of the component allergens.  
 
Lastly, the hybrids could be further combined to construct a hybrid that 
comprises all the four major allergens, which could potentially benefit most patients 
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